United States securities and exchange commission logo





                          May 3, 2022

       James McArthur, Ph.D.
       President and Chief Executive Officer
       PepGen Inc.
       245 Main Street
       Cambridge, MA 02142

                                                        Re: PepGen Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed May 3, 2022
                                                            File No. 333-264335

       Dear Dr. McArthur:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form S-1 filed May 2, 2022

       PGN-EDO51, page 3

   1.                                                   We note your response
to prior comment 1. Given that you did not conduct head-to-head
                                                        trials with EXONDYS 51
and DYNE-251, please remove these comparisons. Please also
                                                        disclose more
information about R6G-PMO so that investors can make a meaningful
                                                        comparison. Please also
expand your disclosure to discuss the meaning of PGN-EDO51
                                                        having "greater
activity" than R6G-PMO.
 James McArthur, Ph.D.
FirstName
PepGen Inc.LastNameJames McArthur, Ph.D.
Comapany
May  3, 2022NamePepGen Inc.
May 3,
Page 2 2022 Page 2
FirstName LastName
       You may contact Tara Harkins at 202-551-3639 or Kevin Kuhar at
202-551-3662 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jane Park at 202-551-7439 or Jeffrey Gabor at 202-551-2544 with any
other questions.



                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences
cc:      James Xu, Esq.